PEAK PHARMACEUTICALS, INC.: 10-K filed 2012-12-26

Name: PEAK PHARMACEUTICALS, INC.: 10-K filed 2012-12-26
Creator: PEAK PHARMACEUTICALS, INC.

What PEAK PHARMACEUTICALS, INC. reported in its annual report filed 2012-12-26 (fiscal FY 2012): 16 published measures, 43 facts as tagged in accession 0001477932-12-004972.

This filing

Form: 10-K (annual report)
Filed: 2012-12-26
Fiscal period: fiscal FY 2012
Accession: 0001477932-12-004972 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All PEAK PHARMACEUTICALS, INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

Period	Value	Unit	Days
At 2012-09-30	8,231	USD
At 2011-09-30	7,608	USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

Period	Value	Unit	Days
At 2012-09-30	35,130	USD
At 2011-09-30	14,284	USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

Period	Value	Unit
At 2012-09-30	-26,899	USD
At 2011-09-30	-6,676	USD
At 2010-09-30	8,916	USD
At 2009-09-30	8,490	USD
At 2008-09-30	14,126	USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

Period	Value	Unit
At 2012-09-30	4,963	USD
At 2011-09-30	4,840	USD
At 2010-09-30	17,470	USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

Period	Value	Unit	Days
2011-10-01 to 2012-09-30	-20,223	USD	366
2007-12-18 to 2012-09-30	-87,899	USD	1749
2010-10-01 to 2011-09-30	-15,592	USD	365
2009-10-01 to 2010-09-30	-23,594	USD	365
2008-10-01 to 2009-09-30	-22,616	USD	365
2007-12-18 to 2008-09-30	-5,874	USD	288

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

Period	Value	Unit	Days
2011-10-01 to 2012-09-30	-18,877	USD	366
2007-12-18 to 2012-09-30	-75,037	USD	1749
2010-10-01 to 2011-09-30	-12,630	USD	365

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

Period	Value	Unit	Days
2011-10-01 to 2012-09-30	19,000	USD	366
2007-12-18 to 2012-09-30	80,000	USD	1749

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

Period	Value	Unit	Days
2011-10-01 to 2012-09-30	220,500,000	shares	366
2010-10-01 to 2011-09-30	220,500,000	shares	365

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

Period	Value	Unit	Days
2011-10-01 to 2012-09-30	0	USD/shares	366
2010-10-01 to 2011-09-30	0	USD/shares	365

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

Period	Value	Unit	Days
At 2012-09-30	220,500,000	shares
At 2011-09-30	220,500,000	shares

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

Period	Value	Unit	Days
At 2012-09-30	38,950	USD
At 2011-09-30	38,950	USD

Total equity including noncontrolling interests

Equity including the portion attributable to noncontrolling interests. It is larger than or equal to parent stockholders equity and is not market capitalization.

Period	Value	Unit	Days
At 2012-09-30	-26,899	USD
At 2011-09-30	-6,676	USD

Pre-tax income or loss from continuing operations

Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.

Period	Value	Unit	Days
2011-10-01 to 2012-09-30	-20,223	USD	366
2007-12-18 to 2012-09-30	-87,899	USD	1749
2010-10-01 to 2011-09-30	-15,592	USD	365

Profit or loss including noncontrolling interests

Net income or loss including the portion attributable to noncontrolling interests. It can differ from the net income attributable to the parent that per-share figures use.

Period	Value	Unit	Days
2011-10-01 to 2012-09-30	-20,223	USD	366
2007-12-18 to 2012-09-30	-87,899	USD	1749
2010-10-01 to 2011-09-30	-15,592	USD	365

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

Period	Value	Unit	Days
2011-10-01 to 2012-09-30	20,223	USD	366
2007-12-18 to 2012-09-30	87,899	USD	1749
2010-10-01 to 2011-09-30	15,592	USD	365

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

Period	Value	Unit	Days
2007-12-18 to 2012-09-30	61,000	USD	1749

Inspect the source

Entity: PEAK PHARMACEUTICALS, INC. / CIK 0001452804
Captured: 2026-09-20T09:05:40.595Z
SEC response SHA-256: 3fd5eb06bfdebffa42021b094c4c379c1efd3c7143204265bf035090db070211

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python

import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001452804.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))